NEW YORK, July 10, 2012 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, Chief Executive Officer, Pamela Palmer, Founder and Chief Medical
Officer, and Jim Welch, Chief
Financial Officer, will co-present at
RetailInvestorConferences.com.
DATE:
|
July 12,
2012
|
TIME:
|
12:00 PM
EDT
|
LINK:
|
www.retailinvestorconferences.com > red "register
/ watch event now" button
|
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time - both in the
presentation hall as well as the company's "virtual trade booth."
If attendees are not able to join the event live on the day of the
conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and
receive event updates.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, the ARX-01 Sufentanil
NanoTab PCA System, which is currently in Phase 3 clinical
development, is designed to solve the problems associated with
post-operative intravenous patient-controlled analgesia which has
been shown to cause harm to patients following surgery because of
the side effects of morphine, the invasive intravenous route of
delivery and the inherent potential for programming and delivery
errors associated with the complexity of infusion pumps. AcelRx has
two additional product candidates which have completed Phase 2
clinical development: ARX-02 for the treatment of cancer
breakthrough pain, and ARX-03 for mild sedation, anxiety reduction
and pain relief for patients undergoing painful procedures in a
physician's office. A fourth product candidate, ARX-04, is a
sufentanil product for the treatment of moderate-to-severe acute
pain, and AcelRx plans to initiate a Phase 2 study funded by a
grant from USAMRMC, contingent on approval of the proposed clinical
protocol for the study by USAMRMC. For additional information about
AcelRx's clinical programs please visit http://www.acelrx.com.
Forward-Looking Statements
Any forward-looking statements in this release are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include all statements relating
to AcelRx's future financial and operating results, access to or
need for investment capital and the growth of AcelRx's overall
business, as well as other statements that can be identified by the
use of forward-looking language, such as "believes," "feels,"
"expects," "may," "will," "should," "seeks," "plans,"
"anticipates," or "intends" or the negative of those terms, or by
discussions of strategy or intentions. Investors are cautioned that
all forward-looking statements involve risks and uncertainties that
could cause actual results, events and developments to differ
materially from our historical experience and our present
expectations or projections. These risks and uncertainties include,
but are not limited to, those described in AcelRx's filings with
the U.S. Securities and Exchange Commission, including without
limitation its Annual Report on Form 10-K for the year ended
December 31, 2011 and its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2012.
About RetailInvestorConferences.com
Since 2010, RetailInvestorConferences.com, created by
BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only
monthly virtual investor conference series that provides an
interactive forum for presenting companies to meet directly with
retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based
investor conferences, Retail Investor Conferences unites PR
Newswire's leading-edge online conferencing and investor
communications capabilities with BetterInvesting's extensive retail
investor audience network and MUNCmedia's sophisticated retail
investor targeting.
SOURCE AcelRx Pharmaceuticals, Inc.